Cargando…

A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)

BACKGROUND : Pembrolizumab is an immune check-point inhibitor (ICI), which acts by blocking the T lymphocyte PD-1 inhibitor receptor. It has been increasingly used in advanced or non-responsive tumours with promising results. However, acute myocarditis is an infrequent but potentially life-threateni...

Descripción completa

Detalles Bibliográficos
Autores principales: Salido Iniesta, Mario, López López, Laura, Carreras Costa, Francesc, Sionis, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649507/
https://www.ncbi.nlm.nih.gov/pubmed/33204987
http://dx.doi.org/10.1093/ehjcr/ytaa214
_version_ 1783607343451209728
author Salido Iniesta, Mario
López López, Laura
Carreras Costa, Francesc
Sionis, Alessandro
author_facet Salido Iniesta, Mario
López López, Laura
Carreras Costa, Francesc
Sionis, Alessandro
author_sort Salido Iniesta, Mario
collection PubMed
description BACKGROUND : Pembrolizumab is an immune check-point inhibitor (ICI), which acts by blocking the T lymphocyte PD-1 inhibitor receptor. It has been increasingly used in advanced or non-responsive tumours with promising results. However, acute myocarditis is an infrequent but potentially life-threatening autoimmune adverse effect related to ICIs. CASE SUMMARY : This case deals with a 69-year-old gentleman on second-line therapy with pembrolizumab for advanced non-small cell lung cancer. Three weeks after first dose, the patient was diagnosed with an autoimmune hepatitis, treated with decreasing corticoid dosage, followed by acute heart failure. On admission, his electrocardiogram (ECG) showed diffuse repolarization changes and a transthoracic echocardiography revealed severe left ventricle impairment (left ventricular ejection fraction 32%). High-sensitivity cardiac troponin was elevated and a coronary angiogram was performed showing non-significant obstructive disease. An autoimmune myocarditis was suspected, and high-dose intravenous corticoid, intravenous vasodilators, and loop diuretics were started with favourable response. Cardiac magnetic resonance (CMR) imaging, performed 2 weeks after clinical onset, revealed extracellular oedema in the anteroseptal-apical left ventricle segments. A new transthoracic echocardiography, performed after 3 months, showed preserved left ventricle ejection fraction. Finally, the patient was readmitted due to an autoimmune myasthenia-like syndrome. DISCUSSION : Acute autoimmune myocarditis related to ICIs is a challenging diagnosis and its incidence has been underestimated in early studies. Endomyocardial biopsy (EMB) is the gold standard test for its diagnosis. Nevertheless, a definite myocarditis diagnosis is possible without EMB when characteristic clinical syndrome, elevated myonecrosis markers, and electrocardiographic, echocardiographic, and CMR changes are present together.
format Online
Article
Text
id pubmed-7649507
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-76495072020-11-16 A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab) Salido Iniesta, Mario López López, Laura Carreras Costa, Francesc Sionis, Alessandro Eur Heart J Case Rep Case Reports BACKGROUND : Pembrolizumab is an immune check-point inhibitor (ICI), which acts by blocking the T lymphocyte PD-1 inhibitor receptor. It has been increasingly used in advanced or non-responsive tumours with promising results. However, acute myocarditis is an infrequent but potentially life-threatening autoimmune adverse effect related to ICIs. CASE SUMMARY : This case deals with a 69-year-old gentleman on second-line therapy with pembrolizumab for advanced non-small cell lung cancer. Three weeks after first dose, the patient was diagnosed with an autoimmune hepatitis, treated with decreasing corticoid dosage, followed by acute heart failure. On admission, his electrocardiogram (ECG) showed diffuse repolarization changes and a transthoracic echocardiography revealed severe left ventricle impairment (left ventricular ejection fraction 32%). High-sensitivity cardiac troponin was elevated and a coronary angiogram was performed showing non-significant obstructive disease. An autoimmune myocarditis was suspected, and high-dose intravenous corticoid, intravenous vasodilators, and loop diuretics were started with favourable response. Cardiac magnetic resonance (CMR) imaging, performed 2 weeks after clinical onset, revealed extracellular oedema in the anteroseptal-apical left ventricle segments. A new transthoracic echocardiography, performed after 3 months, showed preserved left ventricle ejection fraction. Finally, the patient was readmitted due to an autoimmune myasthenia-like syndrome. DISCUSSION : Acute autoimmune myocarditis related to ICIs is a challenging diagnosis and its incidence has been underestimated in early studies. Endomyocardial biopsy (EMB) is the gold standard test for its diagnosis. Nevertheless, a definite myocarditis diagnosis is possible without EMB when characteristic clinical syndrome, elevated myonecrosis markers, and electrocardiographic, echocardiographic, and CMR changes are present together. Oxford University Press 2020-10-04 /pmc/articles/PMC7649507/ /pubmed/33204987 http://dx.doi.org/10.1093/ehjcr/ytaa214 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Reports
Salido Iniesta, Mario
López López, Laura
Carreras Costa, Francesc
Sionis, Alessandro
A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)
title A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)
title_full A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)
title_fullStr A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)
title_full_unstemmed A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)
title_short A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)
title_sort different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-pd-1 t lymphocyte receptor (pembrolizumab)
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649507/
https://www.ncbi.nlm.nih.gov/pubmed/33204987
http://dx.doi.org/10.1093/ehjcr/ytaa214
work_keys_str_mv AT salidoiniestamario adifferenttypeofacutemyocarditisacasereportofacuteautoimmunemyocarditismediatedbyantipd1tlymphocytereceptorpembrolizumab
AT lopezlopezlaura adifferenttypeofacutemyocarditisacasereportofacuteautoimmunemyocarditismediatedbyantipd1tlymphocytereceptorpembrolizumab
AT carrerascostafrancesc adifferenttypeofacutemyocarditisacasereportofacuteautoimmunemyocarditismediatedbyantipd1tlymphocytereceptorpembrolizumab
AT sionisalessandro adifferenttypeofacutemyocarditisacasereportofacuteautoimmunemyocarditismediatedbyantipd1tlymphocytereceptorpembrolizumab
AT salidoiniestamario differenttypeofacutemyocarditisacasereportofacuteautoimmunemyocarditismediatedbyantipd1tlymphocytereceptorpembrolizumab
AT lopezlopezlaura differenttypeofacutemyocarditisacasereportofacuteautoimmunemyocarditismediatedbyantipd1tlymphocytereceptorpembrolizumab
AT carrerascostafrancesc differenttypeofacutemyocarditisacasereportofacuteautoimmunemyocarditismediatedbyantipd1tlymphocytereceptorpembrolizumab
AT sionisalessandro differenttypeofacutemyocarditisacasereportofacuteautoimmunemyocarditismediatedbyantipd1tlymphocytereceptorpembrolizumab